SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (20298)5/9/1998 12:03:00 PM
From: John O'Neill  Respond to of 32384
 
Thanks for info..The dematologist went on to say that RAR's have different selectivity. He mentioned Tazorac which target RAR "b"
and RAR "y"..this is made by Allergan (it's ok but not great).

I wonder if LGND 1550 will be RAR specific and what off label applications it may have.

What do you think the off label use for Panretin or Targretin (or others)
& which show the most promise??

JO



To: Henry Niman who wrote (20298)5/9/1998 11:42:00 PM
From: WTDEC  Read Replies (1) | Respond to of 32384
 
Henry, you will recall that about 2 months ago LGND indicated some important advances in the STAT area at the Incline Village meeting. We discussed the likelihood of the appearance of an important journal article focusing on our BIG breakthrough in small molecules. Have you heard anything recently on the article??

Regards,

Walter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News